TrialBreast cancer research and treatment2017

A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104).

Lori J Goldstein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.